ONCO-FAIR项目:改善瘤化学疗法治疗中的数据互操作性,以重复使用数据
Baptiste Guilbert1, Tristan Rieu2, Denis Delamarre1
1Univ Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, F-35000, Rennes, France.
Studies in health technology and informatics
|August 23, 2024
概括
在ONCO-FAIR项目增强使用HL7FHIR的瘤化疗数据共享. 这提高了数据的互操作性和用于研究的重用,与FAIR原则保持一致.
科学领域:
- 在瘤学瘤学.
- 医疗信息学 医疗信息学
- 数据科学数据科学数据科学
背景情况:
- 化疗数据交换面临互操作性挑战.
- 现有的标准 (PN13,mCODE,OSIRIS) 对全面的瘤数据集成有局限性.
- 公平原则 (可查找,可访问,可互操作,可重复使用) 对于研究中有效利用健康数据至关重要.
研究的目的:
- 通过应用FAIR原则,提高瘤化学疗法治疗中的数据互操作性.
- 整合HL7 FHIR标准,以应对化疗数据交换中的特定挑战.
- 促进健康数据用于研究目的的再利用.
主要方法:
- 利用整合医疗保健企业 (IHE) 框架,包括四个关键阶段.
- 与医疗机构合作,评估当前标准 (PN13,mCODE,OSIRIS) 的局限性.
- 定制了12个HL7FHIR资源,并开发了两个化疗特异的扩展.
- 开发了用于数据建模的FHIR实施指南.
主要成果:
- 成功地定制了HL7 FHIR资源和扩展,以满足化疗特定数据需求.
- 证明了在化疗数据交换中克服互操作性障碍的能力.
- 建立了一种方法方法,使化疗软件与临床数据仓库基础设施保持一致.
结论:
- 上游互操作性对于有效的化疗数据管理和研究至关重要.
- 拟议的HL7基于FHIR的解决方案促进了在瘤学中数据的重复使用,并遵守了FAIR原则.
- 未来的工作包括将方法扩展到其他瘤学数据,并加强下游数据共享.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Nursing Ethical Principles II
935
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
935
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


